Showing results (2231-2240 of 2,317) with videos related to

Sort By:
Pageof 232
Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.
Cell Reports. Medicine|October 4, 2025
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b studyYuxiang Ma, Shaoyan Lin, Qun Chen, et al.
Therapeutic Advances in Medical Oncology|November 5, 2020
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III studyQing Yuan Zhang, Tao Sun, Yong Mei Yin, et al.
JAMA|June 28, 2018
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical TrialJin Li, Shukui Qin, Rui-Hua Xu, et al.
The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Med (New York, N.Y.)|June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trialMingming He, Zhiqiang Wang, Jin Lu, et al.
The Lancet. Oncology|February 14, 2021
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trialBinghe Xu, Min Yan, Fei Ma, et al.
The Lancet. Oncology|August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialYuankai Shi, Li Zhang, Xiaoqing Liu, et al.
Pageof 232